VRTX Vertex Pharmaceuticals Incorporated: Accounting Value per Share

Vertex Pharmaceuticals combines its status as the unrivaled leader in cystic fibrosis therapy with active expansion into genetic engineering and hematology. The history of book value per share helps correlate this growth with tangible assets, where the current value is 80.55. The gradual expansion of the product portfolio effectively mitigates reliance on a single segment, despite regulatory pressure in the US.

This metric is calculated as the difference between total assets and liabilities, divided by the number of shares. It determines the share of net assets due to the security holder upon business liquidation. The monopoly position of Vertex Pharmaceuticals (VRTX) in cystic fibrosis therapy and the launch of new drugs ensure steady growth in equity. By analyzing the book value per common share, an investor identifies the company's real cost base. The trend on this chart helps avoid overpaying for the asset.